Third Arc Bio’s Synergy Platform builds upon the success of T cell engagers, which are highly effective in hematologic malignancies and now are emerging in solid tumors as well. While CD3 engagement alone can provide single agent activity in solid tumors, a second T cell signal can provide full activation and expansion of the immune response. Third Arc Bio accomplishes this by integrating CD28 co-stimulation to the therapeutic approach. We have developed a two-molecule bispecific approach and a single molecule trispecific format. The two formats allow for a tailored approach for each tumor target, depending on the expression profile and clinical approach.
Discovering Best-in-Class Antibodies Starting with Thousands of Binders
The Third Arc Bio Discovery Engine is a leading antibody discovery platform designed to generate and select best-in-class T cell engagers. By leveraging proprietary immunization approaches, advanced selection algorithms, and antibody engineering, we pair the best binders with antibody architecture to maximize therapeutic potential.
Our process involves screening thousands of binders and testing numerous architectures, including trispecifics and masking to select the most promising leads, all while ensuring manufacturability for seamless progression into clinical and commercial supply.
TARGETING DOMAIN
- Epitope selection for optimized MoA
- Antibody with high specificity and superior biophysical properties
- Formatted for high potency and manufacturability
T CELL EFFECTOR DOMAIN
- Proprietary anti-CD3 and anti-CD28 agonists for T cell engagers
- Tuned potency, cytokine sparing
- Novel checkpoint agonists for precise immune regulation
Two Innovative Platforms: Solid Tumors and Immunology & Inflammation (I&I)
By tailoring approaches for each disease mechanism, Third Arc Bio develops immune cell-engaging antibodies that modulate immune cell activity at the site of disease, to transform the treatment paradigm for both oncology and I&I diseases.
Oncology: Synergy Platform
Co-stimulation to Transform Solid Tumor Therapy
For solid tumors, our Synergy Platform leverages CD3 and CD28 co-stimulation to deliver therapies that maximize efficacy while minimizing toxicity.
Two Molecule and One Molecule Approach
SIGNAL 1 ONLY
SIGNAL 1 + SIGNAL 2
SIGNAL 2 ONLY
Third Arc Bio’s Synergy Platform relies on conditionally active CD28 co-stimulation. Alone, our CD28 binders are silent; only in the presence of CD3 signaling (Signal 1) can Third Arc Bio’s proprietary CD28 binders co-stimulate T cells (Signal 2). This approach delivers unprecedented synergy against cancer cells via combined Signal 1 and Signal 2 signaling and has the promise to transform the treatment paradigm for solid tumors.
We continue to expand a compelling pipeline with next-generation solid tumor targets and multispecific architectures.
I&I: Tethering Platform
Tissue-specific Suppression of Immune Cells
For I&I, our Tethering Platform offers a novel approach to precisely and potently suppress harmful immune cells at diseased sites while avoiding systemic immune suppression.
Current autoimmune treatments are largely systemic, which can raise the risk of infection and malignancy while also making combination regimes too toxic. Third Arc Bio addresses the shortcoming of current autoimmune treatments with our Tethering Platform, which localizes checkpoint agonists at the site of disease.
Third Arc Bio’s Tethering Platform creates multispecifics that are designed to home to the site of disease and then cluster to block immune activity. Through novel tissue-specific binders, our multispecific biologics are directed to autoimmune tissues to provide site specific suppression of autoimmune activity. Because clustering only happens at sites of disease, the systemic immune system should be spared thereby providing improved therapeutic index.
